A Phase I/II Study of Amrubicine and Irinotecan in Patients with Advanced Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Amrubicin (Primary) ; Irinotecan (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 08 Jun 2009 New trial record.